GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Appili Therapeutics Inc (OTCPK:APLIF) » Definitions » Inventories, Other

APLIF (Appili Therapeutics) Inventories, Other : $0.00 Mil (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Appili Therapeutics Inventories, Other?

Other inventories including goods for resale, stocks in transit, consignment stocks, etc. Appili Therapeutics's other inventories for the quarter that ended in Dec. 2024 was $0.00 Mil.


Appili Therapeutics Inventories, Other Historical Data

The historical data trend for Appili Therapeutics's Inventories, Other can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Appili Therapeutics Inventories, Other Chart

Appili Therapeutics Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Inventories, Other
Get a 7-Day Free Trial - - - - -

Appili Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Inventories, Other Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Appili Therapeutics Inventories, Other Calculation

Other inventories including goods for resale, stocks in transit, consignment stocks, etc.


Appili Therapeutics Business Description

Traded in Other Exchanges
Address
1344 Summer Street, Suite 21, Halifax, NS, CAN, B3H 0A8
Appili Therapeutics Inc is a biopharmaceutical company. The company is engaged in novel antibiotic and anti-infective therapies to help patients suffering from serious infections. Its anti-infective portfolio currently includes programs namely ATI-1701, ATI-1801.